RT Journal Article
T1 [Immunisation schedule of the Pediatric Spanish Association: 2021 recommendations].
T2 Calendario de vacunaciones de la Asociación Española de Pediatría: recomendaciones 2021.
A1 Álvarez García, Francisco José
A1 Cilleruelo Ortega, María José
A1 Álvarez Aldeán, Javier
A1 Garcés-Sánchez, María
A1 García Sánchez, Nuria
A1 Garrote Llanos, Elisa
A1 Hernández Merino, Ángel
A1 Iofrío de Arce, Antonio
A1 Montesdeoca Melián, Abián
A1 Navarro Gómez, María Luisa
A1 Ruiz-Contreras, Jesús
A1 en representación del Comité Asesor de Vacunas de la Asociación Española de Pediatría (CAV-AEP), 
K1 Adolescent
K1 Adolescente
K1 Calendario de vacunación
K1 Child
K1 Enfermedades inmunoprevenibles
K1 Immunisation schedule
K1 Infant
K1 Lactante
K1 Niño
K1 Vaccine preventable diseases
K1 Vaccines
K1 Vacunas
AB The CAV-AEP annually publishes the immunisation schedule considered optimal for all children and adolescent resident in Spain, taking into account the available evidence. The 2+1 schedule is recommended (2, 4, and 11 months) with hexavalent vaccines (DTPa-VPI-Hib-HB) and with 13-valent pneumococcal conjugate.A 6-year booster is recommended, preferably with DTPa (if available), with a dose of polio for those who received 2+1 schemes, as well as vaccination with Tdpa in adolescents and in each pregnancy, preferably between 27 and 32 weeks. Rotavirus vaccine should be systematic for all infants. Meningococcal B vaccine, with a 2+1 schedule, should be included in routine calendar. In addition to the inclusion of the conjugated tetravalent meningococcal vaccine (MenACWY) at 12 years of age with catch up to 18 years, inclusive, the CAV recommends this vaccine to be also included at 12 months of age, replacing MenC. Likewise, it is recommended in those over 6 weeks of age with risk factors or who travel to countries with a high incidence of these serogroups. Two-dose schedules for triple viral (12 months and 3-4 years) and varicella (15 months and 3-4 years) will be used. The second dose could be applied as a tetraviral vaccine. Universal systematic vaccination against HPV is recommended, regardless of gender, preferably at 12 years, and greater effort should be made to improve coverage. The 9 genotype extends coverage for both genders.
YR 2021
FD 2021
LK http://hdl.handle.net/10668/16943
UL http://hdl.handle.net/10668/16943
LA es
DS RISalud
RD Apr 5, 2025